6 results about "Adrenergic receptor" patented technology

The invention relates to the therapeutic application of multifunctional compounds that act as α2 adrenoreceptor antagonists and cholinesterase inhibitors for the treatment of Alzheimer's disease and other neurodegenerative diseases, or the concomitant use of a mixture of an α2 adrenoreceptor antagonist and a cholinesterase inhibitor to achieve the same effect.

Yohimbine derivatives, their preparation methods, and uses. This invention discloses compounds of Formula I and pharmaceutical compositions comprising compounds of Formula I. The compounds of Formula I of this invention, as adrenaline receptor α2A (ADRA2A) antagonists or partial antagonists, can treat and / or prevent inflammatory bowel disease (IBD), particularly ulcerative colitis (UC), Crohn's disease (CD), or enteritis.

This invention discloses a β3-adrenergic receptor targeting probe GSHP, its preparation method, and its applications. The probe structure is shown below. This probe can visualize the β3-adrenergic receptor (β3-AR) and reversibly monitor the surrounding redox state in real time. Its excellent blood-brain barrier penetration capability enables in vivo brain imaging, which was previously difficult to achieve. This dual-response probe can reversibly and dynamically image the distribution of β3-AR in living cells and its surrounding redox homeostasis under stress conditions, providing direct visual evidence for redox adaptation. Further high-throughput screening using GSHP revealed and validated baicalin as a novel and potent natural inhibitor of β3-AR. Therefore, GSHP provides a multifunctional platform for studying β3-AR-related redox biology and guiding the discovery of treatments for brain diseases.

Intranasal dry powder epinephrine compositions are described herein. The compositions include epinephrine or a pharmaceutically acceptable salt thereof, as well as a stabilizing agent and a carrier. The stabilizing agent is operable to include citric acid, or a pharmaceutically acceptable salt derived therefrom. Such intranasal compositions as described herein are useful in the treatment of health conditions which threaten the central nervous system (CNS) and impede the actions of alpha and beta-adrenergic receptors. Such health conditions include anaphylaxis, bronchospasms, respiratory impairment, organophosphate poisoning, and major adverse cardiac events (MACE).

The current methods and compositions relate to treatment of atrial fibrillation with bucindolol in patients, including patients with heart failure, after being determined to be homozygous Arg389 in the β1 adrenergic receptor gene.

The invention relates to a kit for detecting an active substance, which is an α1-adrenoceptor antagonist, in a sample, wherein the kit comprises: capture antibodies which are designed to bind to the active substance; primary antibodies which are designed to bind to the active substance while the active substance is bound to a capture antibody; and a detection means, wherein the detection means is associated with the primary antibody. The invention also relates to a method for detecting an active substance.